Evidence map›Paper›PMID 39969849›Full record

ArticleLangmuir : the ACS journal of surfaces and colloids2025

Surface Modification of Poly(dimethylsiloxane) Blood Flow Chambers with a Poly(ethylene glycol) Conjugate and Factor XII Inhibitor.

Jake A DeMeulemeester, Alex J Thompson, Joseph A Potkay

Abstract read
In one paragraph

Article in Langmuir : the ACS journal of surfaces and colloids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jake A DeMeulemeesterVA Ann Arbor Healthcare System, Ann Arbor, Michigan 48105, United States.
Alex J ThompsonVA Ann Arbor Healthcare System, Ann Arbor, Michigan 48105, United States.
Joseph A PotkayVA Ann Arbor Healthcare System, Ann Arbor, Michigan 48105, United States.ORCID 0000-0003-0320-7130

Funding

Human-scale microfluidic artificial lungR01HL144660 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI POTKAY, JOSEPH ALLEN · 2019 to 2022
$2.6M
NHLBI NIH HHS R01 HL144660
6 · The paper itself

Abstract

This study is focused on the application of a dual surface coating on poly(dimethylsiloxane) (PDMS) flow chambers, which aims to inhibit the contact activation pathway of coagulation. Polyethylene glycol (PEG) is a commonly used biocompatible molecule due to its hydrophilic nature and capacity to reduce protein adsorption. Corn trypsin inhibitor (CTI) is a selective inhibitor of Factor XII, which is the initial factor responsible for activating the intrinsic pathway of coagulation. By sequentially applying these two coatings to PDMS substrates, we expect the PEG-CTI coating to decrease blood clot formation and reduce fibrinogen deposition on surfaces compared to uncoated surfaces. Our results indicate that the PEG-CTI coating was successful in significantly reducing both cell adsorption and fibrinogen deposition to the surfaces of PDMS flow chambers. This study is a step toward applying PEG-CTI surface coatings to PDMS microfluidic artificial lungs, in which the surface interaction between the PDMS lungs and blood is a critical issue that must be mitigated to realize the full potential of this exciting therapeutic tool.

Indexed as

DimethylpolysiloxanesFactor XIIPolyethylene GlycolsAdsorptionFibrinogenHumansPlant ProteinsSurface PropertiesbaysilonDimethylpolysiloxanesFactor XIIFibrinogenPlant ProteinsPolyethylene Glycolstrypsin inhibitor, Zea mays

Identifiers

PMID39969849
PMCPMC12207897

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.